公司资料
Aquestive Therapeutics 股价、新闻与催化剂
- 股票代码:
- AQST
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
4.29 USD (+0.94%)
收盘价
最后更新: 2026年8月17日
493M USD
市值
股价为何变动
As of Aug 17, 2026, AQST closed up 0.94% at $4.29. No new same-company headline was identified in the current news window.
公司概览
Oral Film Drug Delivery Company
Aquestive Therapeutics develops medicines using proprietary film-based delivery technologies for allergic reactions and other conditions.
Anaphylm
Anaphylm is a postage-stamp-sized sublingual film containing a prodrug of epinephrine for severe allergic reactions, including anaphylaxis. It dissolves without water or swallowing.
PharmFilm Platform
Aquestive's film technology controls drug loading, disintegration, and absorption in a compact dosage form and can be adapted across central nervous system and allergy products.
Non-Injectable Epinephrine Strategy
Anaphylm is intended to offer portable and intuitive epinephrine administration without an autoinjector while producing clinically relevant systemic exposure.
Global Regulatory Opportunity
Aquestive plans to use the Anaphylm clinical package for regulatory applications outside the United States, extending the program into Canada, Europe, the United Kingdom, and other markets.
未来催化剂
- Resubmission of the Anaphylm NDA in the third quarter of 2026.
- Submission of an Anaphylm regulatory application in Canada by the end of 2026.
- Submission of an Anaphylm regulatory application in the European Union in the first quarter of 2027.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。